TiumBio Co Ltd

TiumBio operates with a market capitalization of KRW 233.83 billion and a price-to-book ratio of 5.73, indicating a premium valuation relative to its book value. The company holds KRW 10.70 billion in cash and equivalents but carries a long-term debt of KRW 45.25 billion, resulting in a debt-to-equity ratio of 1.11. The negative operating cash flow of KRW -15.30 billion and free cash flow of KRW -15.63 billion suggest significant liquidity pressure despite a current ratio of 1.11. Profitability metrics are weak, with a return on equity of -42.55% and return on assets of -17.62%. The company reported a net loss of KRW -17.36 billion and an operating loss of KRW -17.27 billion, reflecting challenges in achieving positive earnings. Gross profit of KRW 5.04 billion is insufficient to offset operating expenses, contributing to the net loss. TiumBio's revenue of KRW 12.29 billion is derived from a single business segment, with no disclosed geographic diversification. The company's revenue concentration in a single segment increases exposure to market-specific risks. No material geographic breakdown is available in the latest financials. The company's growth trajectory is uncertain, with no disclosed revenue growth in the latest period. The operating loss and negative cash flows suggest a lack of momentum in scaling operations or improving margins. No specific guidance for the next fiscal year is provided in the available data. Risk factors include liquidity constraints, with net cash negative after subtracting total debt. The company's dilution risk is currently low, but the negative free cash flow and high debt levels could necessitate future equity raises. No recent events or filings are disclosed in the available data. No recent events, such as earnings calls, regulatory updates, or strategic announcements, are disclosed in the available data. The absence of recent filings or transcripts limits visibility into management's strategic direction or operational updates.